Issues in Assessment of Durability of Success in HIV Clinical Trials
View Presentation *Victor DeGruttola, Harvard School of Public Health Keywords: An issue that arises in research on new treatments for HIV infections is that patients generally change therapies after there is evidence of significant toxicities or loss of potency. While one can define a failure endpoint at the time of treatment change, doing so conflates efficacy and toxicity. Therefore it is important to consider how best to estimate efficacy in the presence of dose-limiting toxicities, newer ideas related to causal inference may be useful in this setting.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC